Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345139 | 1.00 | CPB1 (0.50) | CPB1CTSLKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL3345137 | 1.00 | CPB1 (0.50) | CPB1CTSLKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL716913 | 1.00 | CPB1 (0.50) | CPB1CTSLKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL14169340 | 0.86 | ALDH1A1 (0.58) | CPB1CTSLKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL4265690 | 0.85 | CPB1 (0.55) | CPB1CTSLKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL23871461 | 0.85 | ALDH1A1 (0.54) | CPB1CTSLKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL18544185 | 0.85 | ALDH1A1 (0.54) | CPB1CTSLKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL18544476 | 0.85 | ALDH1A1 (0.54) | CPB1CTSLKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL18544213 | 0.85 | ALDH1A1 (0.54) | CPB1CTSLKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL18544475 | 0.85 | ALDH1A1 (0.54) | CPB1CTSLKMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431370-B1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-2431370-A1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | CPB1 507/4885CTSL 1845/4885KMT2A 2546/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | CPB1 2282/4885CTSL 2388/4885KMT2A 3495/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | CPB1 3108/4885CTSL 2437/4885KMT2A 3485/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | CPB1 3108/4885CTSL 2437/4885KMT2A 3485/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | CPB1 3417/4885CTSL 2909/4885KMT2A 3179/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | CPB1 3108/4885CTSL 2437/4885KMT2A 3485/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | CPB1 136/4885CTSL 1522/4885KMT2A 1453/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | CPB1 3433/4885CTSL 2420/4885KMT2A 3461/4885 |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | F2, ECE1, MLLT1 | CPB1 3850/4885CTSL 3622/4885KMT2A 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.